<DOC>
	<DOCNO>NCT00023686</DOCNO>
	<brief_summary>RATIONALE : Internal radiation use radioactive material place directly near tumor kill tumor cell . It yet know whether surgery effective internal radiation treat prostate cancer . PURPOSE : Randomized phase III trial compare effectiveness surgery internal radiation treat patient stage II prostate cancer .</brief_summary>
	<brief_title>Surgery Versus Internal Radiation Treating Patients With Stage II Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare overall survival patient stage II prostate cancer treat radical prostatectomy v brachytherapy . - Compare metastasis-free survival probability survival without symptom patient treat regimen . - Compare side effect treatment regimens patient . OUTLINE : This randomize study . Patients randomize one two treatment arm . - Arm I : Patients undergo radical prostatectomy . - Arm II : Patients undergo brachytherapy implanted iodine I 125 palladium Pd 103 seed Patients follow every 6 month 5 year annually thereafter . PROJECTED ACCRUAL : A total 1,980 patient ( 990 per treatment arm ) accrue study within 5.5 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate within past 120 day T1cT2a , N0 , M0 No bilateral disease Prostatespecific antigen ( PSA ) great 10 ng/mL In patient prior neoadjuvant hormonal therapy ( NHT ) , PSA must less 10 ng/mL prior therapy Gleason score great 6 Prostate gland less 60 cc transrectal ultrasound minimal pubic arch interference OR Prostate gland 60 cc great prior NHT allow prostate size reduce less 60 cc NHT PATIENT CHARACTERISTICS : Age : 75 Performance status : ECOG 02 OR Zubrod 02 Renal : Creatinine great 3 mg/dL Cardiovascular : No significant cardiovascular disease No New York Heart Association class III IV heart disease Other : No malignancy within past 5 year except effectively treat basal cell squamous cell skin cancer malignancy low risk recurrence No condition would preclude study PRIOR CONCURRENT THERAPY : Endocrine therapy : See Disease Characteristics At least 90 day since prior NHT Duration therapy great 120 day No concurrent NHT Radiotherapy : No prior radiotherapy pelvis Surgery : No prior surgery prostate cancer benign disease , include : Transurethral resection prostate Transurethral resection bladder neck Cryotherapy Laser ablation Microwave therapy</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
</DOC>